



Biotech Daily

Friday January 27, 2023

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH EVEN: UNIVERSAL BIO UP 10%; AMPLIA DOWN 4.5%**
- * **RESMED H1 REVENUE UP 10.3% TO \$2.8b, PROFIT UP 6.4% TO \$655m**
- * **MACH 7 H1 RECEIPTS DOWN 24.7% TO \$9m**
- * **UNIVERSAL BIOSENSORS RECEIPTS UP 1.3% TO \$4m**
- * **ATOMO H1 RECEIPTS FALL 77% TO \$1.8m**
- * **PROTEOMICS OPTIONS RAISE \$1.7m**
- * **RHINOMED: CANADA DELAYS RHINOSWAB JUNIOR RAT APPROVAL**
- * **GE TO INTEGRATE IMRICOR 3-D CARDIAC MAPPING SYSTEMS**
- * **CORRECTION: IMMURON**
- * **NEUROTECH ETHICS APPROVAL FOR NTI164 MARIJUANA PSYCH TRIAL**
- * **AUSTRALIAN ETHICAL REDUCES TO 10.7% OF COGSTATE**
- * **RESMED MICHAEL FARRELL EXEC CHAIR, PETER FARRELL EMERITUS**

MARKET REPORT

The Australian stock market was up 0.34 percent on Friday January 27, 2023, with the ASX200 up 25.5 points to 7,493.8 points. Fifteen of the Biotech Daily Top 40 stocks were up, 15 fell, nine traded unchanged and one was untraded.

Universal Biosensors was the best, prior to filing its December quarterly report (see below), up three cents or 10.3 percent to 32 cents, with 30,706 shares traded. Avita climbed 6.4 percent; Compumedics improved 5.6 percent; Actinogen was up 4.4 percent; Opthea climbed 3.3 percent; Orthocell, Paradigm, Prescient and Resmed rose two percent or more; with Clinuvel, Cochlear, Cyclopharm, Medical Developments, Nanosonics, Neuren, Pro Medicus and Telix up by less than one percent.

Amplia led the falls, down 0.4 cents or 4.5 percent to 8.5 cents, with 248,449 shares traded, followed by Antisense down 4.4 percent to 8.7 cents with 398,281 shares traded. Dimerix, Emvision, Imugene, Nova Eye, Pharmaxis, Resonance and Starpharma lost more than three percent; Genetic Signatures, Impedimed, Oncosil and Polynovo shed more than two percent; Mesoblast and Volpara were down more than one percent; with CSL down by half a percent.

RESMED

Resmed says revenue for the six months to December 31, 2022 was up 10.3 percent to \$US1,984,000,000 (\$A2,784,937,852) with net profit after tax up 6.4 percent to \$US466,470,000 (\$A654,783,246).

Resmed said revenue of \$1,761,400,000 came from its sleep and respiratory care products, as well as \$US222,600,000 from its software-as-a-service business.

The company cited both US generally accepted accounting principles (GAAP) and non-GAAP data, saying it used non-GAAP information because it provided better insight when evaluating performance from core operations and provided consistent financial reporting.

Resmed said that research and development expenses were up 8.7 percent to \$US133,062,000, or 6.7 percent of total revenue.

Resmed said non-GAAP diluted earnings per share rose 6.4 percent to \$US3.17, it had cash and equivalents of \$US253,199,000 at December 31, 2022, and it would pay a dividend of 44 US cents for a record date of February 9, payable on March 16, 2023.

Resmed was up 69 cents or 2.1 percent to \$33.65 with 876,842 shares traded.

MACH 7 TECHNOLOGIES

Mach 7 says receipts from customers for the six months to December 31, 2022 were down 24.7 percent to \$9,031,000 compared to the prior corresponding period.

Mach 7 said receipts from customers from its software licences for its image management systems for the three months to December 31, 2022 were down 26.0 percent to \$6,390,000 from the previous record \$8,636,000.

The company said it had a cash burn for the six months to December 31, 2022 of \$5,349,000, with cash and cash equivalents of \$20,605,000 at December 31, 2022.

Mach 7 fell 2.5 cents or 3.3 percent to 74 cents.

UNIVERSAL BIOSENSORS

Universal Biosensors says receipts from customers for the 12 months to December 31, 2022 was up 1.3 percent to \$4,024,000 compared to the prior corresponding period.

Universal Biosensors said receipts from its Sentia wine testing platform and coagulation testing for the three months to December 31, 2022 fell 53.5 percent to \$590,000 compared to the prior corresponding period.

The company said that it had a cash burn of \$738,000 for the three months to December 31, 2022, with cash and equivalents of \$26,825,000 at December 31, 2022.

Universal Biosensors was up three cents or 10.3 percent to 32 cents.

ATOMO DIAGNOSTICS

Atomo says that receipts from customers for the six months to December 31, 2022 fell 76.8 percent to \$1,805,000 compared to the previous corresponding period.

Atomo said that receipts for the three months to December 31, 2022 were down 92.0 percent to \$442,000 from last year's \$5,545,000, which included \$4.1 million in revenue from its sales of severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) rapid antigen tests - also known as Covid-19 antigen tests - and HIV Rapid tests, as well as \$1.4 million from Access Bio (BD: Jan 25, 2022).

The company said it had a cash burn for the three months of \$763,000, with cash and cash equivalents of \$10,161,000 at December 31, 2022.

Atomo was unchanged at 5.5 cents.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it has issued 2,350,000 shares and raised \$1,725,000 before costs on the exercise of unquoted corporate advisory options at 75 cents and 50 cents each. Proteomics said that 2,200,000 corporate advisory options, which were to expire on January 28, 2023, were exercised at 75 cents an option, with 150,000 corporate advisory options, expiring on March 27, 2023, were exercised at 50 cents each.

The company did not disclose the identity of the option holders but said “the option exercise has resulted in long-term shareholders increasing their positions”.

Proteomics was unchanged at \$1.15.

RHINOMED

Rhinomed says Health Canada requires further data to support the use of its Rhinoswab Junior with BTNX’s rapid antigen test, and will delay approval.

Last year, Rhinomed said it had a \$21.6 million deal to supply Canada’s BTNX Inc with Rhinoswab Junior for use in its rapid antigen tests (BD: Apr 7, 2022).

Today, the company said that approval for the BTNX Covid-19 Rapid Response test with the Rhinoswab Junior would be delayed and in turn, would delay the initial shipment of 1.5 million Rhinoswabs.

Rhinomed said the deferral of the shipment may impact its revenue for 2022-'23, but there were no changes to the terms of the agreement with BTNX.

Rhinomed said that BTNX would use its Rhinoswab Adult and Junior in a clinical trial of its Multiplex rapid antigen test for severe-acute-respiratory-syndrome coronavirus-2, influenza A and B and respiratory syncytial virus, expected to finish in March 2023.

Rhinomed was up half a cent or 4.8 percent to 11 cents.

IMRICOR MEDICAL SYSTEMS

Imricor says it has a five-year agreement with GE Healthcare for its three-dimensional (3-D) cardiac mapping systems on GE’s magnetic resonance imaging platform.

Imricor said a “successful collaboration” with the Chicago-based GE Healthcare would enable “cardiac electrophysiology ablation procedures guided by real-time [magnetic resonance imaging] using Imricor’s catheters and other disposable devices, to be performed on the GE Healthcare MRI platform”.

The company did not disclose the commercial terms of the collaboration, but said it was initially for five years, with automatic renewal for one year afterwards.

Imricor said that it was collaborating with the world’s three major magnetic resonance imaging (MRI) manufacturers, including Siemens Healthineers and Phillips, enabling invasive cardiovascular magnetic resonance-guided (ICMR) ablations across their systems (BD: Jun 28, 2022).

Imricor executive chair Steve Wedan said the company was “thrilled at the prospect of expanding the portfolio of MRI scanners that support Advantage-MR and NorthStar-MR technology”.

“The addition of GE Healthcare will give physicians and hospitals significantly more flexibility to use the MRI hardware of their choice, when providing real-time ICMR ablations for their patients,” Mr Wedan said.

“We are grateful to our existing customers who have embraced our real-time ICMR ablation technology and look forward to making the benefits of this technology even more widely available,” Mr Wedan said.

Imricor was unchanged at 27 cents.

IMMURON

Wednesday's edition incorrectly said the US Food and Drug Administration had placed a clinical hold on Travelan for Campylobacter and enterotoxigenic Escherichia coli (ETEC). Immuron chief executive officer Steve Lydeamore told Biotech Daily today that the cow colostrum-based polyclonal antibody is produced in the same manner as Travelan, or IMM-124E, but has been named Campetec.

There are no restrictions on the over-the-counter Travelan for travellers' diarrhoea, nor the Travelan investigational new drug application.

Biotech Daily unreservedly apologizes for the error.

As this is the first correction of the year the sub-editor at fault has been severely admonished, but no further action has been taken, this time.

Immuron fell 0.3 cents or 3.7 percent to 7.9 cents.

NEUROTECH INTERNATIONAL

Neurotech says it has ethics approval for a 15-patient, phase I/II trial of the marijuana-based NTI164 for children with neuro-psychiatric disorders.

Neurotech said it had ethics approval from the Sydney's Children's Hospital at Westmead as part of the multi-site, open-label trial studying the safety and efficacy of its low delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) combination drug, NTI164, in children with paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (Pandas) and paediatric acute-onset neuropsychiatric syndrome (Pans).

The company said the trial would dose children with 5.0 milligrams per kilogram per day of NTI164, increasing weekly by 5.0mg/kg for a period of four weeks until the maximum tolerate dose or 20mg/kg was achieved, and that patients would receive the maximum dose or 20mg/kg/day for eight weeks, with the option to extend, followed by an eight week "weaning" phase, decreasing the dose by 5.0mg/kg/week for four weeks.

Neurotech said the primary endpoints were the revised children's anxiety and depression scale, the clinical global impression-severity and improvement, and that secondary endpoints included the Yale global tic severity scale, as well as other clinical scales.

The company said that it had filed for recruitment to begin at the Paediatric Neurology Unit at Melbourne's Monash Medical Centre and expected recruitment to begin by March, with results expected by the end of 2023.

Neurotech executive director Dr Thomas Duthy said that "to our knowledge, this is the first clinical trial conducted in Pandas/Pans patients with a novel, oral, full-spectrum cannabinoid drug formulation ... to provide initial evidence of clinical efficacy and safety".

"Given the urgent unmet medical need and lack of safe and effective approved therapies, the company intends to rapidly progress development of NTI164 in Pandas/Pans by leveraging available regulatory mechanisms, including orphan drug designations where applicable," Dr Duthy said.

Neurotech was unchanged at 7.1 cents.

COGSTATE

Australian Ethical Investment says it has reduced its holding in Cogstate from 20,271,570 shares (11.69%) to 18,487,247 shares (10.66%).

Australian Ethical said that it sold shares between August 2, 2022 and January 24, 2023, with the single largest sale on September 28, 2022 of 850,000 shares for \$1,697,195 or \$2.00 a share.

Cogstate was unchanged at \$2.00.

RESMED

Resmed says chief executive officer Michael Farrell will replace his father Peter Farrell as chair, with Peter Farrell continuing as chair emeritus, effective from January 25, 2023. Resmed said that Michael Farrell was appointed as chief executive officer on March 1, 2013 and had been a director since assuming the role. The company said that Peter Farrell would continue as an active board member.